Journal of Clinical Oncology, Vol 4, 1470-1480, Copyright © 1986 by American Society of Clinical Oncology

ARTICLES

Follicular lymphoma: prognostic factors for response and survival

CJ Gallagher, WM Gregory, AE Jones, AG Stansfeld, MA Richards, HS Dhaliwal, JS Malpas and TA Lister

One hundred forty-eight patients with newly diagnosed follicular lymphoma were treated over a 12-year period. Twenty-two patients received radiotherapy for stage I and II disease, followed by adjuvant chemotherapy in 14 patients. One hundred thirteen were treated at presentation with short courses of chemotherapy, most often with single- agent chlorambucil for bulky stage II and stages III and IV disease. Thirteen patients were managed expectantly until there was evidence of disease progression. The median survival was 9 years. Patients treated with radiotherapy for stage I and II disease had an 83% relapse-free survival, but those with bulky stage II or stages III and IV disease treated with chemotherapy pursued a remitting and relapsing course with a 70% response rate at initial and subsequent retreatments, but a median duration of remission of 4 years in stage III and 1 year in stage IV disease (P = .041). Patients were observed in relapse and retreatment was administered as appropriate, once every 33 months on average. Poor prognosis patients could be identified by a combination of the presentation characteristics: B symptoms, hepatosplenomegaly, anemia, and abnormal liver function. These factors predicted a poor response to treatment and correlated with a short survival. Histologic subgroups were not associated with differences in survival, but transformation to a diffuse high-grade lymphoma was observed in 23 of the 72 patients (32%) at risk, with a median follow-up of 6 years and 6 months, and was associated with a very poor prognosis. The present treatment strategy has proved successful for most patients with localized disease and those older patients with indolent small volume disseminated follicular lymphoma. New approaches are being investigated for the younger poor prognosis patients.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. O'Shea, C. O'Riain, M. Gupta, R. Waters, Y. Yang, D. Wrench, J. Gribben, A. Rosenwald, G. Ott, L. M. Rimsza, et al. Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation Blood, March 5, 2009; 113(10): 2298 - 2301. [Abstract] [Full Text] [PDF]

				K. J. Thomson, E. C. Morris, A. Bloor, G. Cook, D. Milligan, A. Parker, F. Clark, L. Yung, D. C. Linch, R. Chakraverty, et al. Favorable Long-Term Survival After Reduced-Intensity Allogeneic Transplantation for Multiple-Relapse Aggressive Non-Hodgkin's Lymphoma J. Clin. Oncol., January 20, 2009; 27(3): 426 - 432. [Abstract] [Full Text] [PDF]

				A. J. Al-Tourah, K. K. Gill, M. Chhanabhai, P. J. Hoskins, R. J. Klasa, K. J. Savage, L. H. Sehn, T. N. Shenkier, R. D. Gascoyne, and J. M. Connors Population-Based Analysis of Incidence and Outcome of Transformed Non-Hodgkin's Lymphoma J. Clin. Oncol., November 10, 2008; 26(32): 5165 - 5169. [Abstract] [Full Text] [PDF]

				D. O'Shea, C. O'Riain, C. Taylor, R. Waters, E. Carlotti, F. MacDougall, J. Gribben, A. Rosenwald, G. Ott, L. M. Rimsza, et al. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival Blood, October 15, 2008; 112(8): 3126 - 3129. [Abstract] [Full Text] [PDF]

				M. J. Bishton, M. F. Leahy, R. J. Hicks, J. H. Turner, A. D. McQuillan, and J. F. Seymour Repeat treatment with iodine-131-rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin's lymphoma who had previously responded to iodine-131-rituximab Ann. Onc., September 1, 2008; 19(9): 1629 - 1633. [Abstract] [Full Text] [PDF]

				C. Sebban, P. Brice, R. Delarue, C. Haioun, B. Souleau, N. Mounier, N. Brousse, P. Feugier, H. Tilly, P. Solal-Celigny, et al. Impact of Rituximab and/or High-Dose Therapy With Autotransplant at Time of Relapse in Patients With Follicular Lymphoma: A GELA Study J. Clin. Oncol., July 20, 2008; 26(21): 3614 - 3620. [Abstract] [Full Text] [PDF]

				J. P. Plastaras, E. Glatstein, and S. J. Schuster Commentary: Let the Tail Wag the Dog: The Case for Radioimmunotherapy of Low-Grade Follicular Lymphoma Oncologist, June 1, 2008; 13(6): 655 - 656. [Full Text] [PDF]

				J. Leonard, J. Friedberg, A Younes, D Fisher, L. Gordon, J Moore, M Czuczman, T Miller, P Stiff, B. Cheson, et al. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma Ann. Onc., July 1, 2007; 18(7): 1216 - 1223. [Abstract] [Full Text] [PDF]

				A. Z.S. Rohatiner, L. Nadler, A. J. Davies, J. Apostolidis, D. Neuberg, J. Matthews, J. G. Gribben, P. M. Mauch, T. A. Lister, and A. S. Freedman Myeloablative Therapy With Autologous Bone Marrow Transplantation for Follicular Lymphoma at the Time of Second or Subsequent Remission: Long-Term Follow-Up J. Clin. Oncol., June 20, 2007; 25(18): 2554 - 2559. [Abstract] [Full Text] [PDF]

				S. Montoto, A. J. Davies, J. Matthews, M. Calaminici, A. J. Norton, J. Amess, S. Vinnicombe, R. Waters, A. Z.S. Rohatiner, and T. A. Lister Risk and Clinical Implications of Transformation of Follicular Lymphoma to Diffuse Large B-Cell Lymphoma J. Clin. Oncol., June 10, 2007; 25(17): 2426 - 2433. [Abstract] [Full Text] [PDF]

				J. G. Gribben How I treat indolent lymphoma Blood, June 1, 2007; 109(11): 4617 - 4626. [Abstract] [Full Text] [PDF]

				H. Schulz, J. F. Bohlius, S. Trelle, N. Skoetz, M. Reiser, T. Kober, G. Schwarzer, M. Herold, M. Dreyling, M. Hallek, et al. Immunochemotherapy With Rituximab and Overall Survival in Patients With Indolent or Mantle Cell Lymphoma: A Systematic Review and Meta-analysis J Natl Cancer Inst, May 2, 2007; 99(9): 706 - 714. [Abstract] [Full Text] [PDF]

				M. H. J. van Oers, R. Klasa, R. E. Marcus, M. Wolf, E. Kimby, R. D. Gascoyne, A. Jack, M. van't Veer, A. Vranovsky, H. Holte, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial Blood, November 15, 2006; 108(10): 3295 - 3301. [Abstract] [Full Text] [PDF]

				A. M. Lee, A. J. Clear, M. Calaminici, A. J. Davies, S. Jordan, F. MacDougall, J. Matthews, A. J. Norton, J. G. Gribben, T. A. Lister, et al. Number of CD4+ Cells and Location of Forkhead Box Protein P3-Positive Cells in Diagnostic Follicular Lymphoma Tissue Microarrays Correlates With Outcome J. Clin. Oncol., November 1, 2006; 24(31): 5052 - 5059. [Abstract] [Full Text] [PDF]

				J. Carreras, A. Lopez-Guillermo, B. C. Fox, L. Colomo, A. Martinez, G. Roncador, E. Montserrat, E. Campo, and A. H. Banham High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma Blood, November 1, 2006; 108(9): 2957 - 2964. [Abstract] [Full Text] [PDF]

				S. Inoges, M. Rodriguez-Calvillo, N. Zabalegui, A. Lopez-Diaz de Cerio, H. Villanueva, E. Soria, L. Suarez, A. Rodriguez-Caballero, F. Pastor, R. Garcia-Munoz, et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst, September 20, 2006; 98(18): 1292 - 1301. [Abstract] [Full Text] [PDF]

				W. Hiddemann, M. Kneba, M. Dreyling, N. Schmitz, E. Lengfelder, R. Schmits, M. Reiser, B. Metzner, H. Harder, S. Hegewisch-Becker, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group Blood, December 1, 2005; 106(12): 3725 - 3732. [Abstract] [Full Text] [PDF]

				M. S. Kaminski, J. A. Radford, S. A. Gregory, J. P. Leonard, S. J. Knox, S. Kroll, and R. L. Wahl Re-Treatment With I-131 Tositumomab in Patients With Non-Hodgkin's Lymphoma Who Had Previously Responded to I-131 Tositumomab J. Clin. Oncol., November 1, 2005; 23(31): 7985 - 7993. [Abstract] [Full Text] [PDF]

				R. I. Fisher, M. S. Kaminski, R. L. Wahl, S. J. Knox, A. D. Zelenetz, J. M. Vose, J. P. Leonard, S. Kroll, S. J. Goldsmith, and M. Coleman Tositumomab and Iodine-131 Tositumomab Produces Durable Complete Remissions in a Subset of Heavily Pretreated Patients With Low-Grade and Transformed Non-Hodgkin's Lymphomas J. Clin. Oncol., October 20, 2005; 23(30): 7565 - 7573. [Abstract] [Full Text] [PDF]

				W. Hiddemann, C. Buske, M. Dreyling, O. Weigert, G. Lenz, R. Forstpointner, C. Nickenig, and M. Unterhalt Treatment Strategies in Follicular Lymphomas: Current Status and Future Perspectives J. Clin. Oncol., September 10, 2005; 23(26): 6394 - 6399. [Abstract] [Full Text] [PDF]

				J. P. Leonard, M. Coleman, L. Kostakoglu, A. Chadburn, E. Cesarman, R. R. Furman, M. W. Schuster, R. Niesvizky, D. Muss, J. Fiore, et al. Abbreviated Chemotherapy With Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab for Untreated Follicular Lymphoma J. Clin. Oncol., August 20, 2005; 23(24): 5696 - 5704. [Abstract] [Full Text] [PDF]

				T. A. Lister Improved Survival for Patients With Follicular Lymphoma J. Clin. Oncol., August 1, 2005; 23(22): 4830 - 4831. [Full Text] [PDF]

				J. M. Bennett, M. S. Kaminski, J. P. Leonard, J. M. Vose, A. D. Zelenetz, S. J. Knox, S. Horning, O. W. Press, J. A. Radford, S. M. Kroll, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab Blood, June 15, 2005; 105(12): 4576 - 4582. [Abstract] [Full Text] [PDF]

				L. Song, A. Zlobin, P. Ghoshal, Q. Zhang, C. Houde, S. Weijzen, Q. Jiang, E. Nacheva, D. Yagan, E. Davis, et al. Alteration of SMRT Tumor Suppressor Function in Transformed Non-Hodgkin Lymphomas Cancer Res., June 1, 2005; 65(11): 4554 - 4561. [Abstract] [Full Text] [PDF]

				T. E. Witzig, A. M. Vukov, T. M. Habermann, S. Geyer, P. J. Kurtin, W. R. Friedenberg, W. L. White, H. I. Chalchal, P. J. Flynn, T. R. Fitch, et al. Rituximab Therapy for Patients With Newly Diagnosed, Advanced-Stage, Follicular Grade I Non-Hodgkin's Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group J. Clin. Oncol., February 20, 2005; 23(6): 1103 - 1108. [Abstract] [Full Text] [PDF]

				M.S. Czuczman, A. Koryzna, A. Mohr, C. Stewart, K. Donohue, L. Blumenson, Z.P. Bernstein, P. McCarthy, A. Alam, F. Hernandez-Ilizaliturri, et al. Rituximab in Combination With Fludarabine Chemotherapy in Low-Grade or Follicular Lymphoma J. Clin. Oncol., February 1, 2005; 23(4): 694 - 704. [Abstract] [Full Text] [PDF]

				R. Forstpointner, M. Dreyling, R. Repp, S. Hermann, A. Hanel, B. Metzner, C. Pott, F. Hartmann, F. Rothmann, R. Rohrberg, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group Blood, November 15, 2004; 104(10): 3064 - 3071. [Abstract] [Full Text] [PDF]

				S. Montoto, A. Lopez-Guillermo, A. Altes, G. Perea, A. Ferrer, M. Camos, L. Villela, F. Bosch, J. Esteve, F. Cervantes, et al. Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression Ann. Onc., October 1, 2004; 15(10): 1484 - 1489. [Abstract] [Full Text] [PDF]

				S. Hallmeyer and D. Peace Integrative Tumor Board: Recurrent Lymphoma Integr Cancer Ther, September 1, 2004; 3(3): 239 - 243. [PDF]

				S. Rao, D. Watkins, D. Cunningham, D. Dunlop, P. Johnson, P. Selby, B. W. Hancock, C. Fegan, D. Culligan, S. Schey, et al. Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma Ann. Onc., September 1, 2004; 15(9): 1413 - 1418. [Abstract] [Full Text] [PDF]

				P. Corradini, M. Ladetto, F. Zallio, M. Astolfi, E. Rizzo, S. Sametti, A. Cuttica, R. Rosato, L. Farina, M. Boccadoro, et al. Long-Term Follow-Up of Indolent Lymphoma Patients Treated With High-Dose Sequential Chemotherapy and Autografting: Evidence That Durable Molecular and Clinical Remission Frequently Can Be Attained Only in Follicular Subtypes J. Clin. Oncol., April 15, 2004; 22(8): 1460 - 1468. [Abstract] [Full Text] [PDF]

				A.J. Davies, A.Z.S. Rohatiner, S. Howell, K.E. Britton, S.E. Owens, I.N. Micallef, D.P. Deakin, B.M. Carrington, J.A. Lawrance, S. Vinnicombe, et al. Tositumomab and Iodine I 131 Tositumomab for Recurrent Indolent and Transformed B-Cell Non-Hodgkin's Lymphoma J. Clin. Oncol., April 15, 2004; 22(8): 1469 - 1479. [Abstract] [Full Text] [PDF]

				H. C. Schouten, W. Qian, S. Kvaloy, A. Porcellini, H. Hagberg, H. E. Johnsen, J. K. Doorduijn, M. R. Sydes, and G. Kvalheim High-Dose Therapy Improves Progression-Free Survival and Survival in Relapsed Follicular Non-Hodgkin's Lymphoma: Results From the Randomized European CUP Trial J. Clin. Oncol., November 1, 2003; 21(21): 3918 - 3927. [Abstract] [Full Text] [PDF]

				A. K. Gopal, T. A. Gooley, D. G. Maloney, S. H. Petersdorf, J. F. Eary, J. G. Rajendran, S. A. Bush, L. D. Durack, J. Golden, P. J. Martin, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis Blood, October 1, 2003; 102(7): 2351 - 2357. [Abstract] [Full Text] [PDF]

				B. A. Peterson, G. R. Petroni, G. Frizzera, M. Barcos, C. D. Bloomfield, N. I. Nissen, D. D. Hurd, E. S. Henderson, G. P. Sartiano, J. L. Johnson, et al. Prolonged Single-Agent Versus Combination Chemotherapy in Indolent Follicular Lymphomas: A Study of the Cancer and Leukemia Group B J. Clin. Oncol., January 1, 2003; 21(1): 5 - 15. [Abstract] [Full Text] [PDF]

				A. Viardot, P. Moller, J. Hogel, K. Werner, G. Mechtersheimer, A. D. Ho, G. Ott, T. F.E. Barth, R. Siebert, S. Gesk, et al. Clinicopathologic Correlations of Genomic Gains and Losses in Follicular Lymphoma J. Clin. Oncol., December 1, 2002; 20(23): 4523 - 4530. [Abstract] [Full Text] [PDF]

				T. E. Witzig, I. W. Flinn, L. I. Gordon, C. Emmanouilides, M. S. Czuczman, M. N. Saleh, L. Cripe, G. Wiseman, T. Olejnik, P. S. Multani, et al. Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma J. Clin. Oncol., August 1, 2002; 20(15): 3262 - 3269. [Abstract] [Full Text] [PDF]

				T. Igarashi, Y. Kobayashi, M. Ogura, T. Kinoshita, T. Ohtsu, Y. Sasaki, Y. Morishima, T. Murate, M. Kasai, N. Uike, et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study Ann. Onc., June 1, 2002; 13(6): 928 - 943. [Abstract] [Full Text] [PDF]

				P. McLaughlin Profiling: "Editorial on 'Survival after progression in patients with follicular lymphoma: analysis of prognostic factors' ", by S. Montoto et al. (Ann Oncol 2002; 13: 523-530) Ann. Onc., April 1, 2002; 13(4): 499 - 500. [Full Text] [PDF]

				S. Montoto, A. Lopez-Guillermo, A. Ferrer, M. Camos, A. Alvarez-Larran, F. Bosch, J. Blade, F. Cervantes, J. Esteve, F. Cobo, et al. Survival after progression in patients with follicular lymphoma: analysis of prognostic factors Ann. Onc., April 1, 2002; 13(4): 523 - 530. [Abstract] [Full Text] [PDF]

				E Drewe and R J Powell Clinically useful monoclonal antibodies in treatment J. Clin. Pathol., February 1, 2002; 55(2): 81 - 85. [Abstract] [Full Text] [PDF]

				A. Rambaldi, M. Lazzari, C. Manzoni, E. Carlotti, L. Arcaini, M. Baccarani, T. Barbui, C. Bernasconi, G. Dastoli, G. Fuga, et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma Blood, February 1, 2002; 99(3): 856 - 862. [Abstract] [Full Text] [PDF]

				B. D. Cheson Some Like It Hot! J. Clin. Oncol., October 1, 2001; 19(19): 3908 - 3911. [Full Text]

				M. S. Kaminski, A. D. Zelenetz, O. W. Press, M. Saleh, J. Leonard, L. Fehrenbacher, T. A. Lister, R. J. Stagg, G. F. Tidmarsh, S. Kroll, et al. Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin's Lymphomas J. Clin. Oncol., October 1, 2001; 19(19): 3918 - 3928. [Abstract] [Full Text]

				D. M. Lillington, I. N.M. Micallef, E. Carpenter, M. J. Neat, J. A.L. Amess, J. Matthews, N. J. Foot, B. D. Young, T. A. Lister, and A. Z.S. Rohatiner Detection of Chromosome Abnormalities Pre-High-Dose Treatment in Patients Developing Therapy-Related Myelodysplasia and Secondary Acute Myelogenous Leukemia After Treatment for Non-Hodgkin's Lymphoma J. Clin. Oncol., May 1, 2001; 19(9): 2472 - 2481. [Abstract] [Full Text] [PDF]

				C. D. Williams, C. N. Harrison, T. A. Lister, A. J. Norton, A. K. Blystad, B. Coiffier, G. Taghipour, N. Schmitz, and A. H. Goldstone High-Dose Therapy and Autologous Stem-Cell Support for Chemosensitive Transformed Low-Grade Follicular Non-Hodgkin's Lymphoma: A Case-Matched Study From the European Bone Marrow Transplant Registry J. Clin. Oncol., February 1, 2001; 19(3): 727 - 735. [Abstract] [Full Text] [PDF]

				K. E. Summers, L. K. Goff, A. G. Wilson, R. K. Gupta, T. A. Lister, and J. Fitzgibbon Frequency of the Bcl-2/IgH Rearrangement in Normal Individuals: Implications for the Monitoring of Disease in Patients With Follicular Lymphoma J. Clin. Oncol., January 15, 2001; 19(2): 420 - 424. [Abstract] [Full Text] [PDF]

				T. A. Davis, A. J. Grillo-Lopez, C. A. White, P. McLaughlin, M. S. Czuczman, B. K. Link, D. G. Maloney, R. L. Weaver, J. Rosenberg, and R. Levy Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin's Lymphoma: Safety and Efficacy of Re-Treatment J. Clin. Oncol., September 17, 2000; 18(17): 3135 - 3143. [Abstract] [Full Text] [PDF]

				M. S. Kaminski, J. Estes, K. R. Zasadny, I. R. Francis, C. W. Ross, M. Tuck, D. Regan, S. Fisher, J. Gutierrez, S. Kroll, et al. Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience Blood, August 15, 2000; 96(4): 1259 - 1266. [Abstract] [Full Text] [PDF]

				T. A. Davis, D. G. Maloney, A. J. Grillo-López, C. A. White, M. E. Williams, G. J. Weiner, S. Dowden, and R. Levy Combination Immunotherapy of Relapsed or Refractory Low-Grade or Follicular Non-Hodgkin's Lymphoma with Rituximab and Interferon-{{alpha}}-2a Clin. Cancer Res., July 1, 2000; 6(7): 2644 - 2652. [Abstract] [Full Text]

				I. N. M. Micallef, D. M. Lillington, J. Apostolidis, J. A. L. Amess, M. Neat, J. Matthews, T. Clark, J. M. Foran, A. Salam, T. A. Lister, et al. Therapy-Related Myelodysplasia and Secondary Acute Myelogenous Leukemia After High-Dose Therapy With Autologous Hematopoietic Progenitor-Cell Support for Lymphoid Malignancies J. Clin. Oncol., March 1, 2000; 18(5): 947 - 947. [Abstract] [Full Text] [PDF]

				J. Apostolidis, R. K. Gupta, D. Grenzelias, P. W. M. Johnson, V. I. Pappa, K. E. Summers, A. Salam, K. Adams, A. J. Norton, J. A. L. Amess, et al. High-Dose Therapy With Autologous Bone Marrow Support as Consolidation of Remission in Follicular Lymphoma: Long-Term Clinical and Molecular Follow-Up J. Clin. Oncol., February 1, 2000; 18(3): 527 - 527. [Abstract] [Full Text] [PDF]

				M. Federico, U. Vitolo, P. L. Zinzani, T. Chisesi, V. Clo, G. Bellesi, M. Magagnoli, M. Liberati, C. Boccomini, P. Niscola, et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases Blood, February 1, 2000; 95(3): 783 - 789. [Abstract] [Full Text] [PDF]

				A. S. Freedman, D. Neuberg, P. Mauch, R. J. Soiffer, K. C. Anderson, D. C. Fisher, R. Schlossman, E. P. Alyea, T. Takvorian, H. Jallow, et al. Long-Term Follow-Up of Autologous Bone Marrow Transplantation in Patients With Relapsed Follicular Lymphoma Blood, November 15, 1999; 94(10): 3325 - 3333. [Abstract] [Full Text] [PDF]

				D. Decaudin, E. Lepage, N. Brousse, P. Brice, J.-L. Harousseau, K. Belhadj, H. Tilly, L. Michaux, S. Cheze, B. Coiffier, et al. Low-Grade Stage III-IV Follicular Lymphoma: Multivariate Analysis of Prognostic Factors in 484 Patients--A Study of the Groupe d'Etude des Lymphomes de l'Adulte J. Clin. Oncol., August 1, 1999; 17(8): 2499 - 2499. [Abstract] [Full Text] [PDF]

				J. M. Foran, A. Z.S. Rohatiner, B. Coiffier, T. Barbui, S. A. Johnson, W. Hiddemann, J. A. Radford, A. J. Norton, S. M. Tollerfield, M. P. Wilson, et al. Multicenter Phase II Study of Fludarabine Phosphate for Patients With Newly Diagnosed Lymphoplasmacytoid Lymphoma, Waldenstrom's Macroglobulinemia, and Mantle-Cell Lymphoma J. Clin. Oncol., February 1, 1999; 17(2): 546 - 546. [Abstract] [Full Text] [PDF]

				J. Apostolidis, J. M. Foran, P.W.M. Johnson, A. Norton, J. Amess, J. Matthews, M. Bradburn, T.A. Lister, and A. Z.S. Rohatiner Patterns of Outcome Following Recurrence After Myeloablative Therapy With Autologous Bone Marrow Transplantation for Follicular Lymphoma J. Clin. Oncol., January 1, 1999; 17(1): 216 - 216. [Abstract] [Full Text] [PDF]

				P J Mounter and A L Lennard Classic diseases revisited: Management of non-Hodgkin's lymphomas Postgrad. Med. J., January 1, 1999; 75(879): 2 - 6. [Abstract] [Full Text]

				H. K. Koh, J. O. Jacobson, F. Foss, and R. A. Lew Is Cutaneous T-Cell Lymphoma Curable? Arch Dermatol, September 1, 1995; 131(9): 1081 - 1082. [Abstract] [PDF]

				P. Solal-Celigny, E. Lepage, N. Brousse, F. Reyes, C. Haioun, M. Leporrier, M. Peuchmaur, A. Bosly, Y. Parlier, P. Brice, et al. Recombinant Interferon Alfa-2b Combined with a Regimen Containing Doxorubicin in Patients with Advanced Follicular Lymphoma N. Engl. J. Med., November 25, 1993; 329(22): 1608 - 1614. [Abstract] [Full Text]

				J. O. Armitage Treatment of Non-Hodgkin's Lymphoma N. Engl. J. Med., April 8, 1993; 328(14): 1023 - 1030. [Full Text]